NEW YORK, Jan. 18, 2022 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, has initiated two self-selection ...

Choosing the right erectile dysfunction medication can feel overwhelming for many people who are trying to understand how ED drugs differ in effectiveness, timing, side effects, and cost. With several ...

VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile MOUNTAIN VIEW, Calif., Nov 18, 2009 /PRNewswire ...

72% of Attempts at Intercourse in the First 15 Minutes were Successful MOUNTAIN VIEW, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS,Inc. (Nasdaq: VVUS) today announced new data ...

VIVUS Announces Study Results Showing STENDRA (Avanafil) is Effective for Sexual Activity Within 15 Minutes in Men With Erectile Dysfunction (ED) Data From Successful Placebo-Controlled Study to be ...

Men with erectile dysfunction may not have to plan for sex as far in advance anymore after Vivus won U.S. approval for avanafil, its faster acting rival to Viagra. Subscribe to read this story ad-free ...

NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug ...

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has filed a New Drug Submission (“NDS”) for Avanafil with Health Canada.

MOUNTAIN VIEW, Calif., Aug. 1, 2013 -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it has entered into a Commercial Supply Agreement with Sanofi Chimie ("Sanofi"), a wholly owned subsidiary of ...

It isn't a normal part of aging, according to a urologist.

SINGAPORE--(BUSINESS WIRE)--Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini AP”) have entered into a licensing agreement to ...